Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
07:00am, Tuesday, 17'th Dec 2024
FOSTER CITY, Calif. & LOS ANGELES--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to
GILD Obtains Positive CHMP Opinion for Liver Disease Drug
02:40pm, Monday, 16'th Dec 2024
The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for the treatment of primary biliary cholangitis in adults.
Gilead (GILD) Upgraded to Buy: Here's Why
01:01pm, Monday, 16'th Dec 2024
Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
06:37am, Friday, 13'th Dec 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
05:54pm, Thursday, 12'th Dec 2024
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year.
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
05:30pm, Thursday, 12'th Dec 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will bec
Is Gilead Sciences (GILD) Stock Undervalued Right Now?
10:41am, Thursday, 12'th Dec 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Thursday, 12'th Dec 2024
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleu
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucab
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
12:30pm, Sunday, 08'th Dec 2024
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcom
Gilead Sciences, Inc. (GILD) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
02:39pm, Wednesday, 04'th Dec 2024
Gilead Sciences, Inc. (NASDAQ:GILD ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 11:40 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call P
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
11:10am, Wednesday, 04'th Dec 2024
GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.
Gilead Sciences, Inc. (GILD) Piper Sandler 36th Annual Healthcare Conference (Transcript)
01:47pm, Tuesday, 03'rd Dec 2024
Gilead Sciences, Inc. (NASDAQ:GILD ) Piper Sandler 36th Annual Healthcare Conference December 3, 2024 11:00 AM ET Company Participants Andy Dickinson - Chief Financial Officer Conference Call Particip
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
10:30am, Tuesday, 03'rd Dec 2024
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
